Bioequivalence of MelaxTM Capsule to MobicTM Capsule (Meloxicam 7.5 mg) |
Lee, Ye-Rie
(Department of Drug Development Service, BioCore Co., Ltd.)
Yeom, Seung-Bock (Department of Drug Development Service, BioCore Co., Ltd.) Ko, Youn-Jung (Department of Drug Development Service, BioCore Co., Ltd.) Ko, Jung-Kil (Department of Drug Development Service, BioCore Co., Ltd.) Kim, Ho-Hyun (Department of Drug Development Service, BioCore Co., Ltd., Department of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratories) Lee, Hee-Joo (Department of Drug Development Service, BioCore Co., Ltd., Department of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratories) Lee, Kyung-Ryul (Department of Drug Development Service, BioCore Co., Ltd., Department of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratories) |
1 | S. Noble and J. Balfour, Meloxicam, Drug, 51(3), 424-430 (1996) DOI ScienceOn |
2 | N.M. Davies and N.M. Skjodi, Clinical Pharmacokinetics of Meloxicam, A Cyclooxygenase-2 Preferential Nonsteroidal Anti-Inflammatory Drug. Clinical Pharmacokinetics, 36(2), 115-126 (1999) DOI ScienceOn |
3 | Effect of Food on the Pharmacokinetics of Meloxicam after Oral Administration, Pharmacokinetics, 9(5), 270-276 (1995) |
4 | 식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22) |
5 | Y.J. Lee, Y.G. Kim, M.G. Lee, S.J. Chung, M.H. Lee and C.K. Shim, Analysis of bioequivalence study using logtransformed model. Yakhakhoeji, 44, 308-314 (2000) |
6 | 식품의약품안전청 고시 제 2002-61호, 의약품동등성시험관리규정 (2002.11.22) |